![]() |
市場調查報告書
商品編碼
1930064
全球眼科診斷設備市場:市場規模、佔有率、成長率、產業分析、按類型、應用和地區劃分的考量因素以及未來預測(2025-2034)Ophthalmic Diagnostic Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034 |
||||||
預計2025年全球眼科診斷設備市場規模將達27.2億美元,2026年將成長至28.9億美元,到2034年將達到48.2億美元,預測期內複合年增長率(CAGR)為6.60%。北美地區將在2025年佔市場主導地位,市場佔有率將達到38.20%,這主要得益於該地區較高的眼科手術量、技術應用以及新產品的推出。市場上的主要參與者包括卡爾蔡司醫療技術股份公司 (Carl Zeiss Meditec AG)、拓普康公司 (Topcon Corporation)、尼得克株式會社 (Nidek Co., Ltd.)、愛爾康 (Alcon)、依視路陸遜梯卡集團 (EssilorLuxottica)、佳能醫療系統 (Canon Medical Systems)、Mon Medical Systems Corporation (Zomb Systems)、佳能醫療系統公司 (Zon Medical Systems)、Mon Ophthalmic Systems AG)、哈格-斯特雷特集團 (Haag-Streit Group) 和 Visionix。這些公司正致力於技術創新、策略聯盟和全球擴張,以鞏固其市場地位。
眼科診斷設備包括光學相干斷層掃描 (OCT)、像差儀地形圖系統、眼底照相機、眼科超音波設備、裂隙燈、檢眼鏡和眼壓計。這些設備用於檢測、診斷和監測青光眼、糖尿病視網膜病變、老年黃斑部病變、白內障、屈光不正和其他視覺障礙等眼部疾病。推動市場成長的關鍵因素包括眼部疾病盛行率的上升、技術進步和人口老化。
新冠疫情的影響
新冠疫情暫時擾亂了眼科診斷設備市場。患者就診和擇期手術被推遲,醫療資源被重新分配用於應對疫情。 2020年3月,美國眼科學會建議美國眼科醫師暫停非緊急診療,導致病患就診量大幅下降。供應鏈中斷進一步影響了市場。然而,隨著限制措施的放鬆,患者數量回升,擇期手術恢復,自2021年以來,在人們對眼部健康的日益重視和眼部疾病患病率不斷上升的推動下,市場呈現穩步增長。
市場驅動因素
眼部疾病的成長趨勢:根據世界衛生組織(WHO,2023)的數據,全球約有22億人患有視力障礙。老化、糖尿病和不健康的生活方式等因素正在增加眼部疾病的發生率。這一趨勢推動了對診斷程序和先進眼科設備的需求。
技術進步:人工智慧 (AI) 整合到診斷設備中,提高了眼部疾病檢測的準確性和效率。人工智慧應用,例如用於糖尿病視網膜病變的視網膜影像分析,有助於減輕眼科醫師的負擔並擴大篩檢覆蓋範圍。遠距眼科諮詢和便攜式設備正在擴大醫療服務的可近性,尤其是在偏遠地區。
人口老化加劇:老年人口數量的增加,以及他們更容易患眼病,顯著增加了對眼科診斷設備的需求。
市場限制因子
缺乏熟練的專業人員:訓練有素的眼科技術人員數量有限,限制了市場成長。在美國,僅有不到 6 萬名眼科技術人員為超過 1.9 萬名眼科醫師提供支援(2024 年美國眼科學會報告)。這種供需不平衡限制了先進設備的有效應用。
高成本和監管挑戰:OCT 掃描器和眼底相機等先進設備價格昂貴。美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等監管機構的審批流程複雜,延緩了產品上市。
市場趨勢
人工智慧整合和數位化:人工智慧驅動的診斷、遠距眼科會診和手持設備正在改變眼科產業。 IDx-DR 和Google的 ARDA 系統等創新技術實現了高效的即時診斷。
產品發布和策略聯盟:各公司正透過合作、收購和技術升級來擴展其產品組合。例如,2023年11月,佳能醫療系統與克利夫蘭診所合作,共同改善眼科診斷的影像和IT技術。
依產品類型劃分:
依最終使用者劃分:
The global ophthalmic diagnostic devices market was valued at USD 2.72 billion in 2025 and is projected to grow to USD 2.89 billion in 2026, eventually reaching USD 4.82 billion by 2034, reflecting a CAGR of 6.60% during the forecast period. North America dominated the market in 2025 with a 38.20% share, driven by the high number of ophthalmic procedures, technological adoption, and new product launches. Key players in the market include Carl Zeiss Meditech AG, Topcon Corporation, NIDEK CO., LTD., Alcon Inc., EssilorLuxottica, Canon Medical Systems Corporation, Bausch + Lomb, Ziemer Ophthalmic Systems AG, Haag-Streit Group, and Visionix. These companies are focusing on technological innovations, strategic partnerships, and global expansions to strengthen their market presence.
Ophthalmic diagnostic devices include optical coherence tomography (OCT), aberrometer & topography systems, fundus cameras, ophthalmic ultrasound, slit lamps, ophthalmoscopes, and tonometers. These instruments are used for detecting, diagnosing, and monitoring ocular diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration, cataracts, refractive errors, and other vision impairments. The market growth is primarily driven by increasing prevalence of eye disorders, technological advancements, and the expanding geriatric population.
Impact of COVID-19
The COVID-19 pandemic temporarily disrupted the ophthalmic diagnostic devices market, as patient visits and elective procedures were postponed, and healthcare resources were redirected toward pandemic management. In March 2020, the American Academy of Ophthalmology advised U.S. ophthalmologists to halt non-urgent care, significantly reducing patient visits. Supply chain disruptions further impacted the market. However, as restrictions eased, patient volumes recovered, elective procedures resumed, and the market witnessed steady growth from 2021 onwards, driven by increasing awareness of eye health and a rising prevalence of ocular diseases.
Market Drivers
Rising Prevalence of Eye Disorders: According to the World Health Organization (2023), around 2.2 billion people worldwide suffer from vision impairment. Factors such as aging populations, diabetes, and unhealthy lifestyles are increasing the incidence of eye diseases. This trend drives demand for diagnostic procedures and advanced ophthalmic devices.
Technological Advancements: The integration of Artificial Intelligence (AI) in diagnostic devices improves the accuracy and efficiency of detecting ocular conditions. AI applications, like retinal image analysis for diabetic retinopathy, help reduce ophthalmologists' workload and increase screening coverage. Teleophthalmology and portable devices are expanding accessibility, especially in remote locations.
Growing Geriatric Population: The rising number of elderly individuals susceptible to eye disorders has significantly contributed to the demand for ophthalmic diagnostic devices.
Market Restraints
Shortage of Skilled Professionals: A limited number of trained ophthalmic technicians is restraining market growth. In the U.S., there are fewer than 60,000 ophthalmic technicians supporting over 19,000 ophthalmologists (2024 AAO report). This imbalance limits effective deployment of advanced devices.
High Cost and Regulatory Challenges: Advanced devices such as OCT scanners and fundus cameras are expensive. Regulatory approvals from authorities like the U.S. FDA and European Medicines Agency (EMA) involve complex procedures, which can delay market entry.
Market Trends
AI Integration and Digitalization: AI-driven diagnostics, teleophthalmology, and portable devices are transforming eye care. Innovations such as IDx-DR and Google's ARDA system facilitate efficient point-of-care diagnostics.
Product Launches and Strategic Collaborations: Companies are expanding product portfolios through partnerships, acquisitions, and technological upgrades. For example, in November 2023, Canon Medical Systems collaborated with Cleveland Clinic to improve imaging and IT technologies for ophthalmic diagnostics.
By Product Type:
By End-User:
Competitive Landscape
Key players include Carl Zeiss Meditech AG, Topcon Corporation, Alcon Inc., NIDEK CO., LTD., EssilorLuxottica, Canon Medical Systems, Bausch + Lomb, Ziemer Ophthalmic Systems, Haag-Streit Group, and Visionix. Strategies focus on product launches, global partnerships, and technological innovation. Recent developments include Bausch + Lomb's SeeNa system launch in 2024, Topcon Korea Medical expansion, and Visionix partnerships in Europe and North America.
Conclusion
The ophthalmic diagnostic devices market is projected to grow from USD 2.72 billion in 2025 to USD 4.82 billion by 2034, driven by technological innovation, AI integration, rising prevalence of eye disorders, and aging populations. Hospitals dominate the end-user segment, while OCT leads product type adoption. North America holds the largest market share, and Asia Pacific demonstrates the fastest growth. Strategic collaborations, innovative product launches, and digital solutions are expected to sustain market expansion, improving access to high-quality eye care globally.
Segmentation By Product Type, End-user, and Region
Segmentation By Product Type
By End-user
By Region